NRXS logo

NeurAxis, Inc.

NRXS
Healthcare|Biotechnology|US
$6.24
+0.13 (+2.13%)
Tangible Book / Share
$0.53
Cash / Share
$0.69

Financials

Financial Snapshot

Market Cap
$78.4M
Enterprise Value
$70.3M
Revenue (TTM)
$5.3M
Net Income (TTM)
-$7.9M
Cash & Investments
$8.3M
Net Cash
$8.0M
Free Cash Flow (TTM)
-$5.6M
Operating CF (TTM)
-$5.6M
Debt/Equity
0.04

Cash Runway & Burn Rate

Cash on Hand
$8.3M
Quarterly Burn
$1.4M
Monthly Burn
$468.4K
Est. Runway
~5.9 quarters
MetricTrend202020212022202320242025TTM
Cash & Investments
$1.9M$320.9K$253.7K$78.6K$3.7M$5.0M$8.3M
Operating Cash Flow
-$4.1M-$2.2M-$2.3M-$6.7M-$6.1M-$6.4M-$5.6M
Free Cash Flow
-$4.2M-$2.2M-$2.4M-$6.8M-$6.1M-$6.5M-$5.6M
Capital Expenditure
-$27.7K-$1.4K-$61.2K-$71.8K-$27.8K-$31.1K-$12.2K
Financing Cash Flow
$6.1M$661.1K$2.3M$6.6M$9.7M$7.8M$8.1M

R&D Spending

R&D (TTM)
$748.6K
R&D Intensity
14.1%
R&D Growth vs Prior
+51.7%
MetricTrend202020212022202320242025TTM
Revenue
$1.9M$2.7M$2.7M$2.5M$2.7M$3.6M$5.3M
R&D Expense
$166.8K$203.4K$225.6K$169.3K$206.1K$493.6K$748.6K
R&D % of Revenue
8.6%7.5%8.4%6.9%7.7%13.8%14.1%
SG&A
$5.4M$5.0M$5.5M$8.7M$9.3M$10.3M$11.5M

Income Statement

MetricTrend202020212022202320242025TTM
Revenue
$1.9M$2.7M$2.7M$2.5M$2.7M$3.6M$5.3M
Cost of Revenue
$481.1K$467.7K$297.1K$303.3K$362.0K$562.9K$767.7K
Gross Profit
$1.4M$2.3M$2.4M$2.2M$2.3M$3.0M$4.5M
R&D
$166.8K$203.4K$225.6K$169.3K$206.1K$493.6K$748.6K
SG&A
$5.4M$5.0M$5.5M$8.7M$9.3M$10.3M$11.5M
Operating Income
-$4.1M-$3.0M-$3.4M-$6.7M-$7.2M-$7.8M-$7.7M
Interest Expense
$75.7K$36.9K$417.6K$5.4M$300.7K$74.0K$51.9K
Pretax Income
-$3.7M-$3.0M-$4.8M-$14.6M-$8.2M-$7.8M-$7.7M
Net Income
-$3.7M-$3.0M-$4.8M-$14.6M-$8.2M-$7.8M-$7.9M
EPS (Diluted)
-0.80-0.62-0.78-2.32-1.22-0.95-0.77
EBITDA
-$3.6M-$3.0M-$4.3M-$9.2M-$7.9M-$7.7M-$7.5M
Shares Out. (M)
5.385.388.416.306.929.0812.12

Balance Sheet

MetricTrend202020212022202320242025TTM
Cash & Equivalents
$1.9M$320.9K$253.7K$78.6K$3.7M$5.0M$8.3M
Short-Term Investments
$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Total Current Assets
$2.5M$491.0K$477.0K$242.6K$4.3M$5.7M$9.4M
Total Assets
$2.8M$760.5K$1.5M$509.5K$4.8M$6.4M$10.0M
Total Current Liabilities
$1.0M$1.4M$7.0M$1.9M$2.4M$2.8M$3.1M
Long-Term Debt
$0.00$51.7K$0.00$0.00$0.00$0.00$0.00
Total Liabilities
$1.1M$1.6M$7.1M$1.9M$2.7M$3.0M$3.3M
Stockholders' Equity
$1.6M-$825.7K-$5.6M-$1.4M$2.1M$3.4M$6.7M
Retained Earnings
-$26.1M-$29.2M-$33.9M-$48.6M-$56.8M-$64.6M-$69.7M

Cash Flow Statement

MetricTrend202020212022202320242025TTM
Operating Cash Flow
-$4.1M-$2.2M-$2.3M-$6.7M-$6.1M-$6.4M-$5.6M
Capital Expenditure
-$27.7K-$1.4K-$61.2K-$71.8K-$27.8K-$31.1K-$12.2K
Free Cash Flow
-$4.2M-$2.2M-$2.4M-$6.8M-$6.1M-$6.5M-$5.6M
Investing Cash Flow
-$27.7K-$1.4K-$61.2K-$71.8K-$27.8K-$131.2K-$112.2K
Financing Cash Flow
$6.1M$661.1K$2.3M$6.6M$9.7M$7.8M$8.1M
Issuance of Stock
$4.0M$510.0K$0.00$4.8M$0.00$8.8M$11.9M
Repurchase of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Net Debt Issuance
-$716.9K$151.1K$3.2M$2.1M$4.7M-$281.8K-$242.3K
Stock Based Comp.
$48.8K$48.6K$27.3K$750.0K$1.4M$596.9K$1.3M
Net Change in Cash
$1.9M-$1.6M-$67.2K-$175.1K$3.6M$1.3M$2.3M

Dilution Tracker

Shares outstanding grew 68.8% over 5 years — significant dilution
Shares Outstanding
13M
5-Year Share Growth
+68.8%
Stock Issuance (TTM)
$11.9M
MetricTrend202020212022202320242025TTM
Shares Out. (M)
5.385.388.416.306.929.0812.12
Change vs Prior %
—0.0%56.3%-25.2%9.9%31.3%33.4%
Stock Issuance
$4.0M$510.0K$0.00$4.8M$0.00$8.8M$11.9M
Stock Repurchase
$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Stock Based Comp.
$48.8K$48.6K$27.3K$750.0K$1.4M$596.9K$1.3M

Margins & Profitability

MetricTrend202020212022202320242025TTM
Gross Margin %
75.1%82.8%88.9%87.7%86.5%84.2%85.6%
Operating Margin %
-213.5%-109.1%-125.6%-270.9%-266.5%-219.4%-144.5%
Net Margin %
-193.0%-111.3%-178.0%-594.6%-306.8%-218.5%-148.0%
EBITDA Margin %
-187.3%-108.6%-161.1%-375.1%-294.2%-214.8%-141.1%
FCF Margin %
-215.9%-82.2%-87.9%-275.0%-228.1%-181.1%-106.0%
ROE %
-226.7%366.7%85.8%1042.4%-398.6%-229.5%-173.3%
ROA %
-133.6%-398.2%-322.8%-2870.8%-173.2%-121.8%-78.7%
ROIC %
-210.8%768.7%67.8%565.3%-281.6%-204.7%-109.5%
R&D / Revenue %
8.6%7.5%8.4%6.9%7.7%13.8%14.1%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend202020212022202320242025
Revenue
0.0%41.0%-1.3%-8.4%9.2%32.9%
Gross Profit
0.0%55.5%5.9%-9.7%7.8%29.4%
Operating Income
0.0%27.9%-13.5%-97.6%-7.4%-9.4%
Net Income
0.0%18.7%-57.9%-206.0%43.7%5.4%
EPS (Diluted)
0.0%22.5%-25.8%-197.4%47.4%22.1%
Operating Cash Flow
0.0%46.0%-2.8%-191.3%8.9%-5.5%
Free Cash Flow
0.0%46.3%-5.5%-186.8%9.5%-5.5%
R&D Expense
0.0%22.0%10.9%-25.0%21.7%139.5%
SG&A Expense
0.0%-7.1%10.2%56.3%7.2%11.5%
Total Assets
0.0%-72.7%94.7%-65.6%833.8%34.6%
Book Value / Share
0.0%-150.2%-331.9%66.4%234.1%25.2%
Debt
0.0%41.0%36.3%-62.5%111.1%-12.0%
Diluted Shares
0.0%0.0%56.3%-25.2%9.9%31.3%

Valuation

P/E (TTM)At Loss
P/S14.74
10Y Low / Med / High6.05 / 11.87 / 18.80
P/B11.23
10Y Low / Med / High7.86 / 12.13 / 19.65
EV/EBITDAAt Loss
EV/Revenue13.23
10Y Low / Med / High4.85 / 11.91 / 18.93
P/FCFAt Loss

Intrinsic Value Models (per share)

Tangible Book / Share
$0.53
Net Current Assets / Share
$0.49
Graham Net-Net
$0.46
Cash / Share
$0.69
MetricTrend202020212022202320242025TTM
P/E Ratio
-7.50-9.68-10.53-1.15-1.93-4.78-8.10
P/S Ratio
16.7311.8718.806.836.0511.5514.74
P/B Ratio
19.65-39.11-9.06-11.987.8612.1311.23
EV/EBITDA
-8.50-10.97-11.75-1.84-1.65-4.79-9.37
EV/Revenue
15.9111.9118.936.894.8510.2813.23

Analyst Estimates & Quality

Altman Z-Score
3.45
Safe
Piotroski F-Score
3
Weak

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$8.3M$19.8M$32.7M
Net Income-$6.9M-$2.5M$2.8M
EPS$-0.76$-0.27$0.31
# Analysts (EPS)111

Revenue Segments

By Geography

Segment202320242025
All Other States$844.4K——
CALIFORNIA$601.2K$778.2K$898.2K
FLORIDA$186.8K$150.0K$143.9K
MASSACHUSETTS$127.3K$154.4K$265.2K
OHIO$407.6K$431.3K$578.8K
All other States—$768.0K$1.2M
ILLINOIS—$246.2K$222.4K